02392nas a2200313 4500000000100000008004100001260001200042653003300054653001400087653002000101653001600121653001300137100002000150700002400170700002100194700002100215700002100236700002500257700002600282700002400308700001900332700001200351700001500363700002000378245009800398300001100496520155700507022001402064 2019 d c11/201910aInfectious imported diseases10aScreening10aschistosomiasis10aSchistosoma10aMigrants1 aSalas-Coronas J1 aVázquez-Villegas J1 aLozano-Serrano A1 aSoriano-Pérez M1 aCabeza-Barrera I1 aCabezas-Fernández T1 aVillarejo-Ordóñez A1 aSánchez-Sánchez J1 aVivas-Pérez J1 aBlanc S1 aJiménez M1 aCuenca-Gómez J00aSevere complications of imported schistosomiasis, Spain: A retrospective observational study. a1015083 a

BACKGROUND: Chronic schistosomiasis silently leads to severe organ-specific disorders, such as hydroureter, bladder cancer or portal hypertension in around 10% of infected people in endemic zones. However, in non-endemic areas, information on schistosomiasis' severe complications and their actual prevalence is scarce because diagnosis is usually reached when such complications are well established.

METHODS: Retrospective observational study of data obtained from a screening protocol designed for sub-Saharan migrants including search for stool parasites and schistosoma serology. After screening 3090 sub-Saharans, 326 (10.5%) confirmed cases of schistosomiasis were found, based on detection of ova in feces, urine or in biopsy samples. Another 830 patients (26.9%) were diagnosed of probable schistosomiasis (positive serology and/or suggestive imaging findings).

RESULTS: Only patients with confirmed schistosomiasis were included in the final analysis. Among them, 13 (4%) presented severe complications at the time of diagnosis. Depending on the location, they account for 5% of patients with hepatointestinal schistosomiasis and 3.5% of patients with urogenital infection.

CONCLUSIONS: Targeted systematic screening could reduce the prevalence of severe complications by enabling early diagnosis and treatment. Having indigenous transmission been demonstrated in southern Europe, prevention of future cases in non-endemic countries might be another sound reason supporting such screening.

 a1873-0442